Active transport of L-dopa in the intestine
- PMID: 4700902
- DOI: 10.1038/242463a0
Active transport of L-dopa in the intestine
Similar articles
-
Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2.Am J Physiol. 1998 Jul;275(1):C104-12. doi: 10.1152/ajpcell.1998.275.1.C104. Am J Physiol. 1998. PMID: 9688840
-
Dipeptide transport in isolated intestinal brush border membrane.Biochim Biophys Acta. 1975 Jun 25;394(2):220-6. doi: 10.1016/0005-2736(75)90260-6. Biochim Biophys Acta. 1975. PMID: 1138931
-
The formation in vivo of 3,4-dihydroxyphenylalanine (DOPA) from 3-hydroxy-DL-phenylalanine (m-tyrosine).Acta Pharmacol Toxicol (Copenh). 1974 May;34(5):391-8. doi: 10.1111/j.1600-0773.1974.tb03535.x. Acta Pharmacol Toxicol (Copenh). 1974. PMID: 4406807 No abstract available.
-
Decarboxylase inhibitors.Pharmacol Ther B. 1975;1(3):407-21. doi: 10.1016/0306-039x(75)90047-1. Pharmacol Ther B. 1975. PMID: 772711 Review. No abstract available.
-
Intestinal absorption of peptides.Physiol Rev. 1975 Oct;55(4):537-608. doi: 10.1152/physrev.1975.55.4.537. Physiol Rev. 1975. PMID: 1103167 Review. No abstract available.
Cited by
-
Stereoselective disposition of flurbiprofen in normal volunteers.Br J Clin Pharmacol. 1992 Apr;33(4):369-75. doi: 10.1111/j.1365-2125.1992.tb04054.x. Br J Clin Pharmacol. 1992. PMID: 1576065 Free PMC article.
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
-
Antiparkinsonian agents. Drug interactions of clinical significance.Drug Saf. 1996 May;14(5):343-54. doi: 10.2165/00002018-199614050-00006. Drug Saf. 1996. PMID: 8800629 Review.
-
A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson's disease.BMC Neurol. 2010 Dec 30;10:124. doi: 10.1186/1471-2377-10-124. BMC Neurol. 2010. PMID: 21192784 Free PMC article.
-
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.Drugs. 1998;55 Suppl 1:10-6. doi: 10.2165/00003495-199855001-00002. Drugs. 1998. PMID: 9483165 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources